Friday, March 27, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Mar 27, 2026
FDA approves Denali's Hunter syndrome drug, handing rare disease community a win
background ▾
- •FDA approved first Hunter syndrome treatment targeting neurologic symptoms using heparan sulfate as surrogate biomarker in accelerated approval pathway
- •Approval validates Denali's regulatory strategy and may resolve industry concerns about surrogate endpoints in rare diseases after recent rejections
- •Watch for impact on other pending rare disease candidates, potential policy shifts at FDA leadership, and post-approval efficacy data requirements
Denali TherapeuticsRegenxbioDisc Medicinetividenofusp alfaAvlayahRGX-121
→ Read original articlePolicy•KFF•Mar 26, 2026
New KFF Tracking Poll on Health Information and Trust Finds One in Three Adults Have Used AI Chatbots for Health Advice — The Monitor
background ▾
- •Federal court suspension of ACIP membership changes and childhood vaccine schedule modifications represents a significant regulatory disruption with potential implications for immunization policy and public health guidance
- •Declining public confidence in federal vaccine agencies (fewer than 50% trust) combined with judicial intervention on procedural grounds suggests broader challenges to institutional credibility in vaccine decision-making
- •Growing reliance on AI chatbots for health information (32% of adults) and mental health advice raises questions about pharmaceutical communication strategy, patient education, and regulatory oversight of AI-generated health claims
Policy•Fierce Pharma•Mar 27, 2026
Outspoken ACIP member steps down amid vaccine panel uncertainty: reports
background ▾
- •Federal court has invalidated RFK Jr.'s ACIP appointments and vaccine schedule changes, paralyzing the committee's operations and creating legal questions about the legitimacy of recent CDC immunization guidance
- •High-profile departure of a prominent ACIP member signals internal fractures and suggests the reconstituted committee lacks stability or consensus support from scientific members
- •Monitor the court's final ruling on ACIP's reconstitution, the timeline for resolving vaccine schedule changes, and whether the White House deprioritizes vaccine policy ahead of elections
Policy•KFF•Mar 24, 2026
KFF Tracker: America First MOU Bilateral Global Health Agreements
background ▾
- •U.S. is fundamentally restructuring global health aid through bilateral MOUs requiring partner countries to increase domestic health spending and decrease reliance on U.S. assistance by 2030
- •These agreements will reshape pharmaceutical market dynamics in developing countries as health priorities and procurement budgets shift from U.S.-directed programs to domestically-determined spending
- •Limited public availability of MOU documents and implementation details creates uncertainty about specific drug access implications and which therapeutic areas will be prioritized in each country
Policy•Fierce Pharma•Mar 27, 2026
Novartis sued by breast cancer patient over branded drug websites’ data-sharing practices
background ▾
- •Novartis allegedly shared patient health data from branded drug websites with third-party analytics and advertising platforms without explicit consent, potentially affecting 100,000+ patients
- •The lawsuit challenges pharma industry practices around patient data collection on consumer-facing drug websites and raises regulatory compliance questions regarding ECPA, privacy policy transparency, and reasonable consumer expectations
- •Monitor regulatory response from FDA, FTC, or state attorneys general; similar suits may follow other pharma companies with branded patient websites; expect increased scrutiny of cookie consent mechanisms and third-party data-sharing disclosures in pharma digital marketing
NovartisGoogleContentsquareKisqali
→ Read original articleMarket Access
Market Access•Fierce Pharma•Mar 27, 2026
As questions swirl around ATTR competition, Alnylam plots path to market leadership for Amvuttra
background ▾
- •Amvuttra achieved 35% new-to-brand market share in only three quarters as third market entrant in ATTR-CM, signaling strong physician/patient adoption of the siRNA approach over oral stabilizers
- •Alnylam strategically frames upcoming Wainua competition and tafamidis genericization as net-positive for category expansion rather than margin compression, citing strong first-line positioning and favorable Medicare coverage terms
- •Watch for: Wainua Phase 3 Cardio-TTRansform results in 2025 and whether combination therapy data validates Alnylam's class-effect thesis; monitor tafamidis LOE impact on ATTR-CM pricing/access dynamics post-late 2028
AlnylamAstraZenecaIonisAmvuttravutrisiranWainua
→ Read original articleMarket Access•Fierce Pharma•Mar 27, 2026
Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer
background ▾
- •Lifyorli represents the first FDA-approved selective glucocorticoid receptor antagonist in oncology, with clinical efficacy demonstrated in a hard endpoint (overall survival) in platinum-resistant ovarian cancer
- •The 35% mortality reduction and accelerated approval timeline (earlier than mid-July expectation) suggest strong clinical and commercial potential, with pricing set at $37,900 for 28-day cycle and anticipated broad payer coverage including Medicare/Medicaid
- •Corcept's pipeline strategy now focuses on expanding relacorilant across endometrial, cervical, pancreatic, and prostate cancers following the ovarian cancer validation, while continuing to pursue a path forward in Cushing's syndrome after FDA rejection
Corcept TherapeuticsrelacorilantLifyorlinab-paclitaxel
→ Read original articleMarket Access•Fierce Pharma•Mar 27, 2026
Ionis slashes Tryngolza's price tag by 93% ahead of anticipated label expansion
background ▾
- •93% price reduction ($595K to $40K annually) signals aggressive payer strategy and confidence in sHTG approval, creating competitive advantage over Redemplo
- •Timing ahead of April payer contracting cycles and June FDA decision enables first-mover advantage and seamless 2025 launch in large sHTG market (3M patients, 1M high-risk)
- •Watch for June FDA sHTG decision and Q2-Q3 2025 payer coverage determinations; early contracting success will be critical validation of pricing strategy and commercial projections
Ionis PharmaceuticalsArrowhead PharmaceuticalsTryngolza (olezarsen)Redemplo
→ Read original articleMarket Access•Fierce Biotech•Mar 27, 2026
Novartis pens $2B deal for allergy biotech with potential Xolair successor
background ▾
- •Novartis secures next-gen anti-IgE successor to $1.7B Xolair franchise ahead of biosimilar erosion in U.S. market starting H2 2026
- •Exl-111 employs novel ECRI mechanism designed to achieve faster onset, deeper IgE suppression, and broader disease control compared to conventional anti-IgE antibodies
- •Watch phase 1/2 clinical data readouts for Exl-111 and competitive positioning versus potential biosimilars and other next-gen allergy therapies
NovartisExcellergyRocheExl-111Xolairomalizumab
→ Read original articleMarket Access•Fierce Biotech•Mar 27, 2026
Philips AI cath lab copilot nets FDA clearance
background ▾
- •DeviceGuide FDA clearance represents a significant commercial milestone for Philips-Edwards partnership in the high-growth structural heart market, enabling faster market penetration of AI-assisted transcatheter mitral valve repair
- •Real-time AI guidance reducing procedure duration by ~95% in early case reports could drive adoption by expanding procedural throughput and reducing patient risk, though larger clinical validation is needed
- •Watch for clinical adoption rates, health economic data demonstrating cost-effectiveness, competitive responses from other imaging/device manufacturers, and potential reimbursement coverage decisions from major payers
PhilipsEdwards LifesciencesPascal Ace
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Mar 27, 2026
After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets
background ▾
- •MZE829 achieved 35.6% proteinuria reduction, exceeding the 30% benchmark and showing 62% reduction in the FSGS subset, meeting primary safety endpoint with no serious adverse events
- •Significant investor selloff despite analyst endorsement suggests market skepticism about competitive differentiation versus Vertex's inaxaplin and heterogeneous efficacy across patient populations (diabetes subgroup showed lower efficacy)
- •Maze moving to pivotal phase 3 trial with patient population refinement based on ongoing phase 2 Horizon data; Vertex's phase 2/3 inaxaplin readout expected later in 2024 will be critical competitive marker
Maze TherapeuticsVertex PharmaceuticalsMZE829inaxaplin
→ Read original articleClinical Trials•Fierce Biotech•Mar 27, 2026
Wave crashes after obesity trial tracks 1% dip in body weight over 6 months
background ▾
- •WVE-007 achieved only 0.9% placebo-adjusted weight loss at six months in phase 1, falling far short of investor expectations and the FDA's 5% efficacy benchmark for obesity drugs
- •Wave is betting on body composition metrics (visceral fat reduction, preserved lean mass) as differentiators versus GLP-1 agents, but payers and regulators may prioritize absolute weight loss
- •Success depends on phase 2a data in higher-BMI populations (35-50) starting Q2; if weight loss remains marginal, the program's viability is at serious risk despite management's confidence
Wave Life SciencesArrowhead PharmaceuticalsMizuho SecuritiesWVE-007
→ Read original articleClinical Trials•Fierce Biotech•Mar 27, 2026
Innate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocus
background ▾
- •Innate has terminated IPH6501 phase 1/2 trial to concentrate on what management views as higher-potential pipeline candidates including IPH4502 and lacutamab.
- •The company is pinning significant near-term hopes on the monalizumab phase 3 readout in NSCLC (with AstraZeneca partnership) and IPH4502's early signals of anti-tumor activity in heavily pre-treated solid tumor patients.
- •Watch for: monalizumab phase 3 results, IPH4502 phase 1 expansion data, lacutamab phase 3 initiation in Sézary syndrome, and whether IPH6501 dose-escalation data reveals any unexpected efficacy signals that might affect interpretation of the discontinuation decision.
Innate PharmaAstraZenecaSanofiIPH6501IPH4502lacutamab
→ Read original article